News
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates research on Valneva SE, maintaining Buy rating and lowering target price from €4.50 to €4.40 following Q2 results, projecting rebound in gross margin and likelihood of FDA approval for Lyme disease vaccine candidate LB6V -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Wolford AG announces group results for the period from January to June 2026
Wolford AG announces group results for the period from January to June 2026, showing a stronger earnings performance despite revenue remaining close to the prior year. The transformation program continues towards sustainable profitability -
COMMUNIQUÉ DE PRESSE
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio
Revive plans to expand bucillamine use in biodefence with positive DRDC findings, government opportunities, and complementary therapies, focusing on medical countermeasures -
COMMUNIQUÉ DE PRESSE
Disclosure according to Article 5(1)(b) of the EU Regulation No. 596/2014 and Article 2(3) of the Delegated EU Regulation No. 2016/1052 - 3rd Interim Report and Final Report
Alzchem Group AG completes share buyback program 2025/2026 with the acquisition of 8,316 shares, totaling 62,311 shares repurchased. Detailed reports available on company's website -
-
![Logo de [UNKNOWN]](https://logos.symex.be/img/.jpg)
